Market Overview

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Share:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
Related IBB
The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait
The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue
Related BMY
Q2 13F Roundup: How Buffett, Einhorn, Loeb And Others Adjusted Their Portfolio
The Week Ahead: Nvidia, Retailer Earnings In Focus
Bristol-Myers Squibb Sees Its Composite Rating Rise To 96 (Investor's Business Daily)

The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has experienced volatility amid the release of another spate of earnings reports. 

Even as the earnings season winds down, the upcoming week presents a slew of catalysts for biotech investors to watch. 

Conferences

  • 33rd International Conference on Dental and Oral Health: Aug. 13-14 in Dubai, UAE
  • 17th Annual Congress on Pediatrics & Neonatology: Aug. 13-14 in Osaka, Japan
  • 2018 Wedbush PacGrow Healthcare Conference: Aug. 14-15 in New York
  • 16th Asia Pacific Biotechnology Congress: Aug. 15-16 in Singapore City, Singapore
  • International Conference on Cancer Research and Diagnostics: Aug. 15-16 in Singapore City, Singapore
  • Asia-Pacific Dermatology and Cosmetology Conference: Aug. 16-17 in Tokyo, Japan

PDUFA Dates

Amicus Therapeutics, Inc. (NASDAQ: FOLD) awaits an FDA verdict Monday on its NDA for Migalastat, which is being tested for treating patients 16 years and older with Fabry disease and amenable mutations.

The FDA is set to decide on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s lumacaftor and ivacaftor combo for cystic fibrosis patients ages 1-2. The PDUFA date for the pipeline candidate is set for Wednesday.

Bristol-Myers Squibb Co (NYSE: BMY) has a incoming decision from the FDA Thursday, as the agency is set to issue its verdict on the company's sBLA for Opdivo for treating small-cell lung cancer.

Clinical Trial Results

Early Q3 Schedule

  • Altimmune Inc (NASDAQ: ALT) is due to release Phase 1 results for its anthrax treatment candidate Nasoshield.

See Also: Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Earnings

Tuesday

  • Athenex Inc (NASDAQ: ATNX)
  • Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)
  • Cytori Therapeutics Inc (NASDAQ: CYTX)
  • Myriad Genetics, Inc. (NASDAQ: MYGN)
  • Tecogen Inc (NASDAQ: TGEN)
  • Reshape Lifesciences Inc (NASDAQ: RSLS)
  • OncoCyte Corp (NYSE: OCX)

Wednesday

  • Altimmune Inc (NASDAQ: ALT)

Thursday

  • Vascular Biogenics Ltd (NASDAQ: VBLT)

IPOs

  • Aridis Pharmaceuticals plans to offer 2 million shares in an IPO, with the pricing expected in the $13-$15 range. The company seeks to list the shares on the Nasdaq under the ticker symbol ARDS.

IPO Quiet Period Expiry

  • Rubius Therapeutics Inc (NASDAQ: RUBY)
  • Crinetics Pharmaceuticals Inc (NASDAQ: CRNX)
  • Allakos Inc (NASDAQ: ALLK)
  • Constellation Pharmaceuticals Inc (NASDAQ: CNST)
  • Replimune Group Inc (NASDAQ: REPL)
  • Provention Bio Inc (NASDAQ: PRVB)

Posted-In: Biotech Earnings News Previews FDA IPOs Top Stories Trading Ideas Best of Benzinga

 

Related Articles (ALT + ALLK)

View Comments and Join the Discussion!

Economic Data Scheduled For Monday

Barron's Picks And Pans: Abercrombie, Equinix, Kraft Heinz, Twitter And More